Jul 8, 2019 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.

Oct 7, 2024 · Investigating the role of selenium in people with PAH. PAH is a type of pulmonary hypertension (PH) caused by the narrowing of the pulmonary arteries, which are the blood vessels that supply the lungs. This leads to high blood pressure and may cause right heart failure, the most common cause of death among PAH patients.

Nov 22, 2024 · The study, “ Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,” was published in Lung. PAH is marked by high blood pressure in the vessels that carry blood through the lungs. People with congenital heart disease (CHD), a broad category that encompasses problems with heart structure or function from birth ...

Aug 22, 2018 · “Mylan has a strong history of leading the way in creating important access to generic medicines, and we’re excited to continue that tradition by offering the first generic to Adcirca Tablets,” Heather Bresch, CEO of Mylan, said in a press release.. “Mylan offers more than 650 products in the U.S., and the addition of Tadalafil Tablets strengthens our …

Nov 27, 2024 · These top-line findings in the ongoing ZENITH trial (NCT04896008), testing the Merck treatment against a placebo while on background therapy, led an independent data monitoring committee to recommend the trial be stopped early. All enrolled patients now are invited to enter the open-label SOTERIA (NCT04796337) extension study and be …

Sep 27, 2024 · According to the company, the new preclinical data “provide the most compelling evidence to date that CS014 offers a disease modifying approach to PAH and related pulmonary vascular diseases by robustly reversing pulmonary pathological [disease-causing] vascular remodeling and fibrosis,” or tissue thickening and scarring.

ALG-801 found safe, well tolerated in Phase 1 study, per developer. PAH is caused by the narrowing of the pulmonary arteries — the blood vessels that carry blood through the lungs — which restricts blood flow and causes high blood pressure, or hypertension. It also makes the heart work harder to pump blood through the body, which can lead to right heart failure in advanced disease stages.

Dec 16, 2024 · An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by …

Oct 9, 2024 · Approved treatments for people with PH-ILD lacking in many countries. In a previous Phase 1 study (NCT04041648) assessing L606’s pharmacokinetics — its movement into, through, and out of the body — in healthy adults, the treatment showed therapeutic levels for up to 12 hours, with a blood plasma peak concentration seven times lower than Tyvaso, the company reported.

Nov 13, 2024 · The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages 18 to 80.To be eligible, participants must not be able to conceive children and must be able to walk between 100 to 450 meters (328 to 1,476 feet) in six minutes.